Peter Simmonds runs a research group in University of Oxford. Very interested in the broader evolution of viruses and constraints under which they are placed.
Oxford, England
Joined June 2017
- Tweets107
- Following67
- Followers835
- Likes136
Peter Simmonds retweeted
Before #COVID19, when was the last #coronavirus #pandemic? Some have argued for 1889-1892 for the zoonosis of human #OC43 from bovine coronavirus, but in our new paper: journals.plos.org/plosone/ar…, we suggest 1899-1900, based on a review and replication of existing molecular data.
Peter Simmonds retweeted
Have you ever wondered how nucleic acid editing pathways (APOBEC, ADAR, and epitranscriptomics) might impact the adaptation of zoonotic viruses to humans? Of course you have! Lucky for you, we have a new review in COVIRO considering just that issue: authors.elsevier.com/c/1gtX3…
Peter Simmonds retweeted
The largest study to date on the viruses residing within our tissues
Unmasking the tissue-resident eukaryotic DNA virome in humans academic.oup.com/nar/advance…
Peter Simmonds retweeted
Come and work with some fantastic people (Oxford/UCL) on using genomics to improve safety of transfusion and transplantation: jobs.ac.uk/job/CKU178/projec…
jobs.ac.uk/job/CKV942/post-d…
Fully funded Oxford PhDs:
ndm.ox.ac.uk/study/dphil-the…
Fully funded UCL PhD:
jobs.ac.uk/job/CKJ558/phd-st…
Peter Simmonds retweeted
Fantastic thread - we report here a total of 139 EV-D68 cases from Europe, most of them in September and numbers are likely to increase. A timely reminder that you will only find what you are looking for!
1. Europe is seeing an upswing in cases of an infection that has been linked to a polio-like phenomenon called #AFM — acute flaccid myelitis — according to a report today in @Eurosurveillanc. Enterovirus D68 is thought to trigger AFM in some kids. eurosurveillance.org/content…
Peter Simmonds retweeted
Are you ready and looking for it! Did you know EV-D68 is back?
Thankful for the great collaboration! @ENPEN_ESCV @KimBenschop
@TheaKFischer @Simmonds_Lab
@ESCVirology @Eurosurveillanc
eurosurveillance.org/content…
Peter Simmonds retweeted
Our review of the ZAP antiviral pathway and how it specifically targets viruses is out in @AnnualReviews. Thank you to @stuartjdneil & @Swanson_Chad. annualreviews.org/doi/abs/10…
Peter Simmonds retweeted
See you there!
The #ESCV2021 Conference is coming to you!
Wherever you are, we can learn together, reshaping our community and raising standards of #ClinicalVirology. More of what you can expect from the #ESCV2021 programme below : ow.ly/L6g450FbmyH
Peter Simmonds retweeted
See you there!
The 23rd ESCV Annual Meeting will take place as a fully virtual event in 2021. #ESCV2021 is scheduled for September 15-17 and will present an outstanding programme covering the most recent discoveries in #ClinicalVirology including the topic of Sars-Cov-2. ow.ly/Nnba50Ei6L6
Peter Simmonds retweeted
Check out our early data on SARS-CoV-2 detection in ITU patients, including SNP PCR method for variant detection. Big thanks to all participants and collaborators 👍 @jeremydratcliff @Simmonds_Lab @AndelLestcourt @7davidroberts @Menon_Cambridge @msh_manu
medrxiv.org/content/10.1101/…
Peter Simmonds retweeted
Now on MedRxiv: Virological and serological characterization of COVID-19 ICU patients in the REMAP CAP trial w/ @HarvalaHeli, @Simmonds_Lab, @Menon_Cambridge and others. B.1.1.7 data included!
A 🧵 of our (NON PEER REVIEWED) major results 1/1
medrxiv.org/content/10.1101/…
Peter Simmonds retweeted
In wild-type virus - probably. But, no reductions seen in counts in seropositive B.1.1.7 infection, so something is different. Await clinical data to draw conclusions, but possible explanations include accelerated disease course and/or different sensitivity to immune response
This quoted post is unavailable.
Peter Simmonds retweeted
The fantastic global meeting for picornavirus research "EUROPIC" will be in the UK in 2022 👇#EUROPIC2022
Calling all picornavirologists! The organisers are hoping to be able to host the next Europic meeting in Harrogate, UK in June 2022. We would be grateful if you could take a minute to register your interest at the link
microbiologysociety.org/even… #virology
Peter Simmonds retweeted
Our view point on prolonged SARS-CoV-2 infection is finally published. We still have so much to learn about SARS-CoV-2. Check out: Understanding the outcomes of COVID-19 – does the current model of an acute respiratory infection really fit? @Simmonds_Lab microbiologyresearch.org/con…
Peter Simmonds retweeted
Despite a slight Covid delay, our paper is now live on PLoS Path. Excellent work by Yao-Tang Lin and Stephen Chiweshe and collaboration with @Simmonds_Lab and @WilsonLabCVR. “Human cytomegalovirus avoids detection by ZAP and TRIM25 regulates ZAP splicing.”
journals.plos.org/plospathog…
Peter Simmonds retweeted
Check out our work on Virological testing and convalescent plasma - back to basics! Big thanks to everybody involved. medrxiv.org/content/10.1101/…
Peter Simmonds retweeted
We found extensive SARS-CoV-2 variation shared among individuals - due wide transmission bottlenecks and localised transmission? @kiddomicrobio @HumanGeneticsOx @tanyagolubchik @mdhall272 @LucaFerrettiEvo @ChristoPhraser @OxfordViromics @CovidGenomicsUK biorxiv.org/content/10.1101/…
Peter Simmonds retweeted
Now it has officially started - the first patient recruited to the convalescent plasma domain of REMAP-CAP by @msh_manu.
**HOT NEWS**: @msh_manu has just recruited first patient to the Convalescent Plasma Domain of @remap_cap. Privelege for me to involved in this #TeamScience with @NHSBT Dave Roberts; @AndelLestcourt; @msh_manu; @agordonICU; @ICNARC; @PaulMouncey; @KathyRowan101; @HarvalaHeli
Peter Simmonds retweeted
Clinical trial approved to help the NHS treat COVID-19 patients using plasma gov.uk/government/news/clini…
